Stanford Downgrades Maxygen (MAXY) to Hold
More News related to MAXY
- Maxygen, Inc. Commences Dutch Auction Tender Offer to Repurchase 6,557,377 Shares of Common Stock
- Maxygen Reports Third Quarter 2009 Financial Results
- Maxygen (MAXY) Announces Resignation of CEO & CFO
- Maxygen (MAXY) Announces Consummation of Joint Venture Transaction With Astellas
- Maxygen (MAXY) Reports Q2 Loss of $0.15, Misses by 4c
Stanford Group downgrades Maxygen (Nasdaq: MAXY) from Buy to Hold.
Maxygen, Inc. operates as a biopharmaceutical company with a focus on developing improved versions of protein drugs.
Related Categories
DowngradesStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
